Clinical trial
A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma
NCT04428047 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma
- Lead sponsor
- UNICANCER
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 4, 2021
- Completion date
- January 7, 2022
- Enrollment
- 7 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.